Ablynx N.V. | Income Statement

Fiscal year is January-December. All values EUR Millions.
2013
2014
2015
2016
2017
Sales/Revenue
32,951
31,694
34,060
33,821
35,055
Cost of Goods Sold (COGS) incl. D&A
14,049
12,445
13,169
12,504
13,594
Gross Income
18,902
19,249
20,891
21,317
21,461
SG&A Expense
13,302
13,034
14,399
14,586
15,455
EBIT
-
-
-
6,731
6,015
Unusual Expense
1,125
607
1,474
1,607
1,208
Non Operating Income/Expense
535
389
584
877
1,013
Interest Expense
457
441
416
379
346
Pretax Income
4,602
5,658
5,243
5,678
5,530
Income Tax
763
1,214
709
1,326
1,722
Equity in Affiliates
35
52
22
134
104
Consolidated Net Income
3,874
4,392
4,512
4,486
3,912
Net Income
3,716
4,273
4,411
4,395
3,791
Net Income After Extraordinaries
3,716
4,156
4,535
4,081
852
Net Income Available to Common
3,716
4,390
4,287
4,709
3,791
EPS (Basic)
2.81
3.34
3.28
3.66
6.71
Basic Shares Outstanding
1,323
1,316
1,306
1,287
1,257
EPS (Diluted)
2.77
3.30
3.25
3.63
6.66
Diluted Shares Outstanding
1,339
1,331
1,321
1,296
1,267
EBITDA
9,823
9,988
10,486
9,721
9,167
Other Operating Expense
-
-
-
-
9
Non-Operating Interest Income
49
102
57
56
56
Minority Interest Expense
158
119
101
91
121

About Ablynx

View Profile
Address
54, rue La Boétie
Paris Ile-de-France 75008
France
Employees -
Website http://www.sanofi.com
Updated 09/14/2018
Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes & cardiovascular, established prescription products and generics, together with research, development and production activities.